HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yuichi Takatsuka Selected Research

Anthracyclines

2/2014[Efficacy and safety of eribulin for metastatic breast cancer patients].
1/2014A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance.
8/2013A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
7/2009Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yuichi Takatsuka Research Topics

Disease

55Breast Neoplasms (Breast Cancer)
03/2022 - 07/2002
29Neoplasms (Cancer)
12/2021 - 07/2002
16Neoplasm Metastasis (Metastasis)
03/2021 - 01/2007
9Stomach Neoplasms (Stomach Cancer)
10/2011 - 10/2003
2Neutropenia
08/2008 - 11/2004
2Nausea
10/2007 - 07/2002
2Edema (Dropsy)
10/2007 - 01/2005
1Diplopia (Double Vision)
03/2022
1Lymphoma (Lymphomas)
12/2021
1Lymphatic Metastasis
12/2021
1Brain Neoplasms (Brain Tumor)
12/2019
1Dyslexia (Alexia)
12/2019
1Eye Diseases (Eye Disease)
12/2019
1Necrosis
12/2019
1Disease Progression
01/2018
1Residual Neoplasm
04/2016
1Amenorrhea
04/2016
1Bone Resorption
12/2015
1Adenocarcinoma
11/2014
1Hemorrhage
11/2014
1Obesity
01/2014
1Wounds and Injuries (Trauma)
11/2013

Drug/Important Bio-Agent (IBA)

17Estrogen ReceptorsIBA
12/2019 - 06/2008
12human ERBB2 proteinIBA
10/2018 - 01/2014
12TamoxifenFDA LinkGeneric
11/2014 - 10/2004
11Progesterone Receptors (Progesterone Receptor)IBA
12/2019 - 06/2008
10Hormones (Hormone)IBA
03/2021 - 05/2006
10Paclitaxel (Taxol)FDA LinkGeneric
03/2020 - 10/2003
6Anastrozole (Arimidex)FDA LinkGeneric
11/2014 - 05/2006
6Docetaxel (Taxotere)FDA Link
01/2014 - 01/2003
5Phenobarbital (Luminal)FDA Link
07/2015 - 01/2014
5Cyclophosphamide (Cytoxan)FDA LinkGeneric
07/2010 - 10/2004
5Fluorouracil (Carac)FDA LinkGeneric
07/2010 - 10/2004
4AnthracyclinesIBA
02/2014 - 07/2009
3ErbB Receptors (EGF Receptor)IBA
10/2018 - 06/2015
3eribulinFDA Link
10/2018 - 02/2014
3Trastuzumab (Herceptin)FDA Link
10/2018 - 07/2009
3Estrogens (Estrogen)FDA Link
04/2016 - 01/2014
3Epirubicin (Ellence)FDA LinkGeneric
07/2010 - 01/2005
2130-nm albumin-bound paclitaxelIBA
10/2018 - 10/2018
2Biomarkers (Surrogate Marker)IBA
04/2016 - 08/2013
2Aromatase InhibitorsIBA
11/2014 - 06/2010
2Toremifene (Fareston)FDA Link
05/2014 - 07/2010
2taxaneIBA
02/2014 - 08/2013
2orantinib (SU6668)IBA
01/2014 - 08/2013
2Biological ProductsIBA
01/2014 - 01/2014
2Tyrosine Kinase InhibitorsIBA
01/2014 - 08/2013
2Cytochrome P-450 CYP2D6 (CYP2D6)IBA
09/2010 - 03/2010
2Capecitabine (Xeloda)FDA Link
07/2009 - 05/2008
2Doxorubicin (Adriamycin)FDA LinkGeneric
01/2006 - 01/2003
2Pharmaceutical PreparationsIBA
10/2004 - 07/2002
1Leuprolide (Lupron)FDA LinkGeneric
12/2019
1Bevacizumab (Avastin)FDA Link
12/2019
1pertuzumabIBA
10/2018
1Carcinoembryonic AntigenIBA
02/2018
1AntigensIBA
02/2018
1DenosumabFDA Link
03/2017
1Zoledronic Acid (Zometa)FDA Link
03/2017
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
12/2016
1GemininIBA
03/2016
1pyridinolineIBA
12/2015
1Collagen Type I (Type I Collagen)IBA
12/2015
1Diphosphonates (Bisphosphonates)IBA
12/2015
1Fulvestrant (Faslodex)FDA Link
07/2015
1Ribosomal Protein S6 Kinases (S6 Kinase)IBA
06/2015
1Proteins (Proteins, Gene)FDA Link
06/2015
1TOR Serine-Threonine KinasesIBA
06/2015
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
06/2015
1Mitogen-Activated Protein KinasesIBA
06/2015
1Phosphatidylinositols (Phosphatidylinositol)IBA
06/2015
1Epidermal Growth Factor (EGF)IBA
11/2014
1AcidsIBA
11/2014
1ElementsIBA
11/2014
1diethylenetriamineIBA
11/2014
1GadoliniumIBA
11/2014
1Inosine Monophosphate (IMP)IBA
11/2014
1Gadolinium DTPA (Magnevist)FDA Link
11/2014
1Selective Estrogen Receptor Modulators (SERM)IBA
05/2014
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2014
1Messenger RNA (mRNA)IBA
08/2013
1Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA
12/2012

Therapy/Procedure

25Therapeutics
03/2021 - 02/2004
23Drug Therapy (Chemotherapy)
03/2021 - 01/2003
9Mastectomy (Mammectomy)
12/2021 - 02/2004
6Segmental Mastectomy (Lumpectomy)
03/2022 - 01/2005
6Neoadjuvant Therapy
04/2016 - 01/2005
5Lymph Node Excision (Lymph Node Dissection)
12/2021 - 11/2014
5Combination Drug Therapy (Combination Chemotherapy)
10/2011 - 01/2006
3Radiotherapy
03/2022 - 10/2005
2Mammaplasty (Breast Reconstruction)
11/2016 - 11/2012
1Local Anesthesia
12/2021
1Palliative Care (Palliative Therapy)
03/2021
1Breast Implants (Breast Implant)
03/2020
1Craniotomy
12/2019
1Aftercare (After-Treatment)
01/2018
1Colectomy
11/2015
1Combined Modality Therapy
11/2014
1Skin Transplantation (Skin Grafting)
11/2013
1Radical Mastectomy
11/2013
1Tissue Expansion Devices (Tissue Expander)
11/2012